BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1290 related articles for article (PubMed ID: 31171886)

  • 1. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
    Choi C; Yoo GS; Cho WK; Park HC
    World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for hepatocellular carcinoma.
    Zongyi Y; Xiaowu L
    Cancer Lett; 2020 Feb; 470():8-17. PubMed ID: 31811905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials.
    Harding JJ
    Future Oncol; 2018 Sep; 14(22):2293-2302. PubMed ID: 29663837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint therapy in liver cancer.
    Xu F; Jin T; Zhu Y; Dai C
    J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors for hepatocellular carcinoma.
    El Dika I; Khalil DN; Abou-Alfa GK
    Cancer; 2019 Oct; 125(19):3312-3319. PubMed ID: 31290997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Bai J; Liang P; Li Q; Feng R; Liu J
    Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
    Cheng AL; Hsu C; Chan SL; Choo SP; Kudo M
    J Hepatol; 2020 Feb; 72(2):307-319. PubMed ID: 31954494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.
    Hato T; Goyal L; Greten TF; Duda DG; Zhu AX
    Hepatology; 2014 Nov; 60(5):1776-82. PubMed ID: 24912948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of PD-1 and CTLA-4: A potent immunotherapeutic approach for hepatocellular carcinoma.
    Hou K; Xu X; Ge X; Jiang J; Ouyang F
    Biofactors; 2024; 50(2):250-265. PubMed ID: 37921427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
    Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
    Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
    Hu ZI; Ho AY; McArthur HL
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy.
    Hage C; Hoves S; Ashoff M; Schandl V; Hört S; Rieder N; Heichinger C; Berrera M; Ries CH; Kiessling F; Pöschinger T
    PLoS One; 2019; 14(7):e0219517. PubMed ID: 31291357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
    Harding JJ; El Dika I; Abou-Alfa GK
    Cancer; 2016 Feb; 122(3):367-77. PubMed ID: 26540029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological and clinical implications of immune checkpoint blockade in human cancer.
    Kim HD; Park SH
    Arch Pharm Res; 2019 Jul; 42(7):567-581. PubMed ID: 30843144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.
    Brown ZJ; Yu SJ; Heinrich B; Ma C; Fu Q; Sandhu M; Agdashian D; Zhang Q; Korangy F; Greten TF
    Cancer Immunol Immunother; 2018 Aug; 67(8):1305-1315. PubMed ID: 29959458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of Hepatocellular Carcinoma.
    Heinrich B; Czauderna C; Marquardt JU
    Oncol Res Treat; 2018; 41(5):292-297. PubMed ID: 29705790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.
    Moreno-Cubero E; Larrubia JR
    World J Gastroenterol; 2016 Jul; 22(28):6469-83. PubMed ID: 27605882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. State of clinical research of radiotherapy/chemoradiotherapy and immune checkpoint inhibitor therapy combinations in solid tumours-a German radiation oncology survey.
    Käsmann L; Eze C; Dantes M; Roengvoraphoj O; Niyazi M; Belka C; Manapov F
    Eur J Cancer; 2019 Feb; 108():50-54. PubMed ID: 30648629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.